KRAS and neoplasm: In a retrospective analysis of the PEAK, FIRE-3, and CALGB/SWOG80405 trials, this trend was also apparent when including subjects with any RAS tumor mutation, rather than just those with KRAS exon 2 tumor mutations [13–15].